Soleno Therapeutics Inc. announced select preliminary financial and operating results for the fourth quarter and full-year 2025. The company reported preliminary unaudited full-year 2025 net revenue related to U.S. sales of VYKAT™ XR, since its second quarter launch, is expected to be in the range of $189 million to $191 million. Preliminary unaudited fourth quarter 2025 net revenue is expected to be in the range of $90 million to $92 million. Since launch through December 31, 2025, Soleno received 1,250 total new patient start forms, including 207 in the fourth quarter, representing approximately 12.5% of the total U.S. VYKAT XR addressable market. These figures are preliminary, unaudited, and may not represent all information necessary for a complete understanding of Soleno's financial condition as of December 31, 2025. The company anticipates announcing full fourth quarter and full-year 2025 financial results in late February 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.